Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07297160 · ClinicalTrials.gov registry record · Phase 1
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
A Phase 1 study, sponsored by Baylor College of Medicine.
- Not yet
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT07297160 is a Phase 1 study that has not yet begun recruiting, run by Baylor College of Medicine. The registered enrollment target is 88 participants.
The verdict
NCT07297160, a Phase 1 study, has not yet begun recruiting, sponsored by Baylor College of Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study is for patients who have a type of cancer that expresses the protein CD70, which includes lymphoma (lymph gland cancer), myeloma and solid tumors including some sarcomas and kidney cancers, and the cancer has come back or has not gone away after standard of care treatment. As there are limited or no remaining standard treatments available to treat this cancer, patients are being asked to volunteer to be in a gene transfer research study using special immune cells to create a specialized immune cell that will recognize a protein called CD70 that is expressed on the outside surface of the tumor cells in the body. This research study combines different ways of fighting disease by using T cells and "arming" them to recognize a specific protein on cancer cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. T cells by themselves have been used to treat patients with cancers and have shown promise, but have not been strong enough to cure most patients. The protein used in this study is called anti-CD70. It has been developed from human CD27 on normal T cells, since it is the natural binding partner that can connect with CD70. This anti-CD70 protein sticks to tumor cells when it binds to CD70. CD70 binders have been used to treat people with different types of cancers. For this study, anti-CD70 has been changed so that instead of floating free in the blood it is now joined to the T cells. When binder is joined to a T cell in this way it is called a chimeric receptor or "CAR T cell". The doctors then made another change to cause these T cells to kill any cell that has CD70. This causes the "CAR T cells" to kill blood cancer cells which are confirmed to have CD70. In the laboratory, investigators have found that T cells work better if there are proteins added that stimulate T cells. The anti-CD70 (CD27) protein is unique because it can bind to CD70 on tumor cells but also stimulat
Interventions
- BIOLOGICAL Dose Level 2
- BIOLOGICAL Dose Level 3
- BIOLOGICAL Dose Level -1
- BIOLOGICAL Dose Level 1 (starting dose level)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2026-06 |
| Est. Completion | 2044-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07297160
The ClinicalTrials.gov registry entry for NCT07297160 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dose Level 2 is the first listed.
NCT07297160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07297160 about?
NCT07297160 is a clinical study titled "CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors". This study is for patients who have a type of cancer that expresses the protein CD70, which includes lymphoma (lymph gland cancer), myeloma and solid tumors including some sarcomas and kidney cancers, and the cancer has come back or has not gone away after standard of care treatment. As there are l...
What is the current status of trial NCT07297160?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2026-06. Estimated completion is 2044-12.
What interventions are being tested in trial NCT07297160?
The interventions under investigation include: Dose Level 2 (BIOLOGICAL), Dose Level 3 (BIOLOGICAL), Dose Level -1 (BIOLOGICAL), Dose Level 1 (starting dose level) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07297160?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.